Clinical data | |
---|---|
Other names | F901318 |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
Chemical and physical data | |
Formula | C28H27FN6O2 |
Molar mass | 498.562 gยทmol |
Olorofim (F901318) is an experimental antifungal drug being developed for invasive mold infections. If approved it would be a first-in-class medication (for the orotomide class). In 2023, the FDA decided not to approve the drug and to request more data about the safety of the drug. Olorofim does not inhibit growth of Candida species.
References
- Neoh, Chin Fen; Jeong, Wirawan; Kong, David CM; Slavin, Monica A (2023). "The antifungal pipeline for invasive fungal diseases: what does the future hold?". Expert Review of Anti-infective Therapy. 21 (6): 577โ594. doi:10.1080/14787210.2023.2203383. PMID 37057677. S2CID 258135111.
- ^ Wiederhold, Nathan P. (2020). "Review of the Novel Investigational Antifungal Olorofim". Journal of Fungi. 6 (3): 122. doi:10.3390/jof6030122. ISSN 2309-608X. PMC 7557671. PMID 32751765.
- "FDA Passes on Olorofim Despite Critical Need for Antifungals". Medscape.